FORE Biotherapeutics Secures $75M in Series D Financing and CEO Transition

Philadelphia, PA, August 23, 2023 (Business Wire) -- FORE Biotherapeutics has successfully concluded its Series D financing round, securing a substantial $75 million. In conjunction with this financing announcement, Matthew E. Ros will be stepping down from his role as CEO and member of the Board of Directors at FORE Biotherapeutics. In his stead, Shawn M. Leland, PharmD, RPh, an advisor to SR One and the former Founder, President, and CEO of Elevation Oncology, has been appointed as the interim CEO and a member of the Board of Directors.

Read full article here.